Related references
Note: Only part of the references are listed.Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
Mohamed-Eslam F. Mohamed et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings
Lisa A. Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials
Ben Klunder et al.
CLINICAL PHARMACOKINETICS (2019)
1024 Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates
T. Song et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
Mohamed-Eslam F. Mohamed et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
Mohamed-Eslam F. Mohamed et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
The multidimensional burden of psoriasis
P. Gisondi
BRITISH JOURNAL OF DERMATOLOGY (2018)
P843 Upadacitinib-induced endoscopic improvement is associated with modulation of pathways involved in Crohn’s disease pathogenesis
D Aguilar et al.
Journal of Crohns & Colitis (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity
Mohamed-Eslam F. Mohamed et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
Ben Kluender et al.
CLINICAL PHARMACOKINETICS (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
SAFETY AND EFFICACY OF ABT-494 (UPADACITINIB), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM CELEST
William J. Sandborn et al.
GASTROENTEROLOGY (2017)
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib
Mohamed-Eslam F. Mohamed et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
Mohamed-Eslam F. Mohamed et al.
CLINICAL PHARMACOKINETICS (2016)
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
Joel M. Kremer et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Share Paper
